Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.

Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.

Item
http://www.wikidata.org/entity/Q44710527
Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AMLPrevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group.MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group.Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.Clinical implications of FLT3 mutations in pediatric AML.FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report.KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891.Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.
P2860

Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.

Item
http://www.wikidata.org/entity/Q44710527
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Pilot study of idarubicin-base ...... ren's Cancer Group Study 2941.
@en
Pilot study of idarubicin-base ...... ren's Cancer Group Study 2941.
@nl
type
label
Pilot study of idarubicin-base ...... ren's Cancer Group Study 2941.
@en
Pilot study of idarubicin-base ...... ren's Cancer Group Study 2941.
@nl
prefLabel
Pilot study of idarubicin-base ...... ren's Cancer Group Study 2941.
@en
Pilot study of idarubicin-base ...... ren's Cancer Group Study 2941.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Pilot study of idarubicin-base ...... ren's Cancer Group Study 2941.
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921